Perspectives in Immunotherapy: meeting report from Immunotherapy Bridge (Naples, November 30th-December 1st, 2022)

• Published in: Journal of translational medicine Vol. 21; no. 1; pp. 488 - 21
• Main Authors: Ascierto, Paolo A, Avallone, Antonio, Bifulco, Carlo, Bracarda, Sergio, Brody, Joshua D, Emens, Leisha A, Ferris, Robert L, Formenti, Silvia C, Hamid, Omid, Johnson, Douglas B, Kirchhoff, Tomas, Klebanoff, Christopher A, Lesinski, Gregory B, Monette, Anne, Neyns, Bart, Odunsi, Kunle, Paulos, Chrystal M, Powell, Jr, Daniel J, Rezvani, Katayoun, Segal, Brahm H, Singh, Nathan, Sullivan, Ryan J, Fox, Bernard A, Puzanov, Igor
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 20.07.2023; BioMed Central; BMC
• Subjects: Analysis; Antigens; Biomarkers; Cancer therapies; Cancer vaccines; Care and treatment; Cellular therapy; Checkpoint inhibitors; Clinical trials; Combination therapy; Cytotoxicity; Diagnosis; Dosage and administration; Genetic engineering; Genotype & phenotype; Graft versus host disease; Humans; Immune checkpoint inhibitors; Immune response; Immunotherapy; Immunotherapy, Adoptive; Italy; Leukemia; Lymphocytes; Meeting Report; Melanoma; Melanoma - pathology; Neurotoxicity; Patient outcomes; Patients; Proteins; T cell receptors; Toxicity; Tumor Microenvironment; Vaccine; Italy; United States; Biomarkers; Checkpoint inhibitors; Vaccine; Tumor microenvironment; Combination therapy; Immunotherapy
• ISSN: 1479-5876; 1479-5876
• DOI: 10.1186/s12967-023-04329-7

The discovery and development of novel treatments that harness the patient's immune system and prevent immune escape has dramatically improved outcomes for patients across cancer types. However, not all patients respond to immunotherapy, acquired resistance remains a challenge, and responses are poor in certain tumors which are considered to be immunologically cold. This has led to the need for new immunotherapy-based approaches, including adoptive cell transfer (ACT), therapeutic vaccines, and novel immune checkpoint inhibitors. These new approaches are focused on patients with an inadequate response to current treatments, with emerging evidence of improved responses in various cancers with new immunotherapy agents, often in combinations with existing agents. The use of cell therapies, drivers of immune response, and trends in immunotherapy were the focus of the Immunotherapy Bridge (November 30th-December 1st, 2022), organized by the Fondazione Melanoma Onlus, Naples, Italy, in collaboration with the Society for Immunotherapy of Cancer.